Spain – Pharmaceutical products – Suministro de medicamentos de uso humano que contiene los principios activos siguientes: alpelisib, asciminib, basiliximab, brolucizumab, canakinumab, capmatinib, ceritinib, dabrafenib, eltrombopag, midostaurina, ofatumumba, ribociclib, ruxolitinib, secukinumab, siponimod y trametinib, con destino a los centros del ámbito de la sanidad pública valenciana

closed

Dirección General de Gestión Económica, Contratación e Infraestructuras de la Conselleria de Sanidad · 20897030133463

Read the notice at ted-eu ↗

Value

€255m

Published

12 Mar 2025

Deadline

—

Type

opportunity

33600000 · Medical equipment, pharmaceuticals & personal careES521ES522ES523

Description

uministro de medicamentos de uso humano que contiene los principios activos siguientes: alpelisib, asciminib, basiliximab, brolucizumab, canakinumab, capmatinib, ceritinib, dabrafenib, eltrombopag, midostaurina, ofatumumba, ribociclib, ruxolitinib, secukinumab, siponimod y trametinib, con destino a los centros del ámbito de la sanidad pública valenciana

Key facts

Procedure: comp-tend
Contact: scontratacion_san@gva.es
Category: supplies

What a subscription adds to this notice

The documents — every attachment, with its text extracted and searchable
Qualification — the notice scored against your company profile
Tracking and alerts — a pipeline for your bids, and the matching notices by email
The API and MCP — the same record in your own tools and your AI assistant

Start your 7-day free trial Sign in

Provenance

Source: ted-eu
Notice id: 160593-2025
First seen: 22 Aug 2026
Last updated: 29 Aug 2026

Licence EU reuse — Commission Decision 2011/833/EU ↗

View at source ↗GET /api/v1/tenders/ea17d3bf-bfa5-4a1e-88cb-ada2c7f3b1ff

The source notice is authoritative — verify deadlines and documents there before bidding.